142 related articles for article (PubMed ID: 17457044)
1. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
Posadas EM; Undevia S; Manchen E; Wade JL; Colevas AD; Karrison T; Vokes EE; Stadler WM
Cancer Biol Ther; 2007 Apr; 6(4):490-3. PubMed ID: 17457044
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
Huang H; Menefee M; Edgerly M; Zhuang S; Kotz H; Poruchynsky M; Huff LM; Bates S; Fojo T
Clin Cancer Res; 2010 Mar; 16(5):1634-41. PubMed ID: 20179242
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
Ott PA; Hamilton A; Jones A; Haas N; Shore T; Liddell S; Christos PJ; Doyle LA; Millward M; Muggia FM; Pavlick AC
PLoS One; 2010 Jan; 5(1):e8714. PubMed ID: 20098694
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
Burotto M; Edgerly M; Velarde M; Balasubramaniam S; Drabkin H; Gormaz JG; O'Sullivan C; Madan R; Fojo T
Oncologist; 2017 Aug; 22(8):888-e84. PubMed ID: 28679644
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
[TBL] [Abstract][Full Text] [Related]
10. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
[TBL] [Abstract][Full Text] [Related]
11. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
14. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Zhuang SH; Agrawal M; Edgerly M; Bakke S; Kotz H; Thambi P; Rutt A; Balis FM; Bates S; Fojo T
Cancer; 2005 May; 103(9):1932-8. PubMed ID: 15800893
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
[TBL] [Abstract][Full Text] [Related]
17. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Eng C; Kindler HL; Nattam S; Ansari RH; Kasza K; Wade-Oliver K; Vokes EE
Ann Oncol; 2004 Jun; 15(6):928-32. PubMed ID: 15151950
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of pemetrexed in patients with metastatic renal cancer.
Thödtmann R; Sauter T; Weinknecht S; Weissbach L; Blatter J; Ohnmacht U; Hanauske A
Invest New Drugs; 2003 Aug; 21(3):353-8. PubMed ID: 14578684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]